The two main product categories in cell and gene therapies are cell treatment and gene therapy. Cell therapy aims to heal illnesses and diseases by regenerating or changing certain cell types, or by supplying cells to deliver medicine throughout the body. The patient's cells are initially produced or modified outside of the body while using cell therapy. The patient's own cells (autologous cells) or those from a donor may be used (allogeneic cells). In order to treat disorders, gene therapy either replaces or introduces genes into cells in vivo (inside the body) or ex vivo (outside the body) (ex vivo). In addition to rising R&D spending by pharmaceutical companies, the market is growing as a result of rising rates of cancer and other target diseases.

During the Covid-19 pandemic, the market for manufacturing services for cell and gene therapies declined due to the limitations on running capacity imposed by the government and the disruption of the supply chain and logistical infrastructure. This has led to an increase in demand for these services, which is projected to have a significant impact on market growth. Additionally, BioCardia's application for an Investigational New Drug (IND) to start a Phase I/II clinical trial of COVID-19 stem cell therapy was authorised by the US Food and Drug Administration (FDA). This will result in an increase in the use of contract manufacturing services.

The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Bluebird Bio Inc., Boehringer Ingelheim, Catalent Inc., Cellular Therapeutics, F. Hoffmann-La Roche Ltd, Hitachi Chemical Co. Ltd., Lonza, Merck KGaA, Miltenyi Biotec, Novartis AG, Samsung Biologics, Takara Bio Inc., Thermo Fisher Scientific, Wuxi Advanced Therapies.

By Therapy Type: Based on the Therapy Type, Global Cell & Gene Therapy Manufacturing Services Market is segmented as; Cell Therapy Manufacturing (Stem Cell Therapy, Non-Stem Cell Therapy), Gene Therapy Manufacturing.

By Scale: Based on the Scale, Global Cell & Gene Therapy Manufacturing Services Market is segmented as; Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing.

By Mode: Based on the Mode, Global Cell & Gene Therapy Manufacturing Services Market is segmented as; Contract Manufacturing, In-house Manufacturing.

By Workflow: Based on the Workflow, Global Cell & Gene Therapy Manufacturing Services Market is segmented as; Cell Processing, Cell Banking, Process Development, Fill & Finish Operations, Analytical and Quality Testing, Raw Material Testing, Vector Production, Other Workflow.

By Region: Based on geography, The Global Cell & Gene Therapy Manufacturing Services Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to the ongoing advancements in the regional industry, the Asia Pacific market is anticipated to present a sizable potential to the market. Manufacturing of cell and gene therapies, scaling out strategies, process development, cost optimization, breakthroughs in CAR-T manufacturing, and commercialization preparation are all areas where best practices are being found.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.